Comparative Pharmacology
Head-to-head clinical analysis: DUAC versus PLIAGLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAC versus PLIAGLIS.
DUAC vs PLIAGLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUAC (clindamycin 1% / benzoyl peroxide 5%) combines clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, a keratolytic and antimicrobial agent that releases free radical oxygen, reducing Propionibacterium acnes and comedones.
Pliaglis is a topical local anesthetic combination of lidocaine and tetracaine. Lidocaine and tetracaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Clindamycin 1% / benzoyl peroxide 5% gel: apply a thin film to affected areas twice daily (morning and evening).
Lidocaine 2.5% and prilocaine 2.5% cream: Apply 1 g per 10 cm² of intact skin; cover with occlusive dressing. Maximum dose: 20 g per application for adults weighing ≥70 kg; for <70 kg, max 10 g. Frequency: Single application, minimum 1 hour before procedure, up to 5 hours.
None Documented
None Documented
Terminal elimination half-life of clindamycin is 2.4 hours in adults with normal renal function; prolonged to 3.7-5.1 hours in hepatic impairment; clinical context: dosing interval may need adjustment in severe hepatic disease.
1.5-2 hours (lidocaine); prolonged in hepatic impairment or heart failure (up to 6-8 hours).
Renal excretion of unchanged clindamycin (10%) and metabolites; biliary/fecal excretion of inactive metabolites; approximately 90% of dose recovered in urine and feces over 6 days.
Renal: 70% (lidocaine and metabolites); fecal: 10% (primarily unchanged); biliary: 20% (metabolites).
Category C
Category C
Topical Acne Agent
Topical Acne Agent